Dr Reddy's Laboratories launch generic version of Ciprodex

Dr Reddy's Laboratories informed the bourses that along with its US subsidiary, it has launched Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent) Otic Suspension, approved by United States Food and Drug Administration (USFDA).

The company’s management said that this launch illustrates its continued commitment to bring affordable generic medicines to the market for patients. At the same time, this product demonstrates that we are actively expanding the depth of the company’s portfolio with its first otic suspension dosage form.

As per IQVIA Health, Ciprodex brand had US sales of approximately US$ 453 million MAT for the most recent twelve-month ending in June 2020.

Dr Reddy's Ciprofloxacin 0.3 per cent and Dexamethasone 0.1 per cent Otic Suspension, USP, is available as 7.5 mL fill in a 10 ml bottle.

The stock of Dr Reddy's Laboratories in Tuesday’s trading session opened in a positive terrain at Rs 4,716 apiece. However, later, it cooled down and dipped  2.1 per cent to touch an intraday low of Rs 4,594.10.

Active pharmaceutical ingredients (API) are the core strength of Dr Reddy's Laboratories. The company also manufactures generic medicines with business spread across India, Russia, the US and Germany as well as proprietary products, which includes NCE research, biologics business, and differentiated formulations conducted in the US.